Table 5.
Age-adjusted prevalence and trend in HbA1c treatment target achievement among women and men with self-reported diabetes aged 40–84: the Tromsø Study 1994–2016
| Tromsø 4 | Tromsø 5 | Tromsø 6 | Tromsø 7 | OR (95% CI)* | P value | |
| Target achievement, % (n) | ||||||
| Women | N=97 | N=150 | N=288 | N=496 | ||
| Guideline target† | 70.1 (63) | 67.3 (93) | 79.2 (222) | 56.7 (282) | 0.67 (0.55 to 0.81) | <0.001 |
| Without medication† | 74.0 (17) | 77.5 (37) | 89.3 (75) | 83.6 (130) | 1.26 (0.81 to 1.96) | 0.297 |
| With medication† | 63.9 (35) | 56.3 (53) | 73.1 (144) | 43.8 (146) | 0.59 (0.47 to 0.75) | <0.001 |
| HbA1c ≤7.0% | 57.3 (49) | 52.4 (66) | 60.4 (170) | 56.1 (282) | 0.99 (0.83 to 1.18) | 0.921 |
| HbA1c <7.5% | 62.6 (54) | 61.6 (83) | 73.9 (209) | 66.9 (337) | 1.07 (0.89 to 1.29) | 0.460 |
| Men | N=95 | N=122 | N=318 | N=572 | ||
| Guideline target† | 62.0 (56) | 58.6 (70) | 62.2 (191) | 46.9 (269) | 0.69 (0.57 to 0.82) | <0.001 |
| Without medication† | 71.9 (16) | 65.7 (13) | 84.9 (40) | 76.1 (94) | 1.11 (0.72 to 1.71) | 0.634 |
| With medication† | 55.1 (34) | 58.0 (55) | 57.7 (149) | 38.5 (171) | 0.61 (0.49 to 0.75) | <0.001 |
| HbA1c ≤7.0% | 50.8 (43) | 40.1 (44) | 46.2 (141) | 46.4 (269) | 0.99 (0.84 to 1.18) | 0.943 |
| HbA1c <7.5% | 58.4 (51) | 57.8 (66) | 58.1 (180) | 60.6 (350) | 1.07 (0.90 to 1.27) | 0.461 |
Proportions, OR with CIs and p value for trend are adjusted for age across surveys using generalised estimating equation models. N represents crude numbers.
Sample sizes are varying due to missing data on medication use.
*ORs for proportions are presented per 10 years.
†HbA1c treatment targets according to Norwegian diabetes guidelines at the time of each survey: Tromsø 4: HbA1c <7.5% (>70 years: HbA1c <8.5%); Tromsø 5 and Tromsø 6: HbA1c <7.5% (>75 years: HbA1c <9.0%); Tromsø 7: HbA1c ≤7.0%.
HbA1c, glycated haemoglobin.